LRRC15 and neoplasm: ABBV-085, a LRRC15 antibody drug conjugate used to deliver the potent antimitotic drug monomethyl auristatin E (MMAE), demonstrated preclinical efficacy against LRRC15 in in vivo models of NSCLC, resulting in localization of the MMAE at high levels in the tumor microenvironment and killing tumor cells by the cell-permeable effects of MMAE [138].